TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Very Early Versus Delayed Angiography +/- Intervention on Outcomes in Patients With NSTEMI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* 18 years of age and over~* Patients presenting to hospitals with a clinical diagnosis of non-ST elevation myocardial infarction comprising:~  * Ischaemic symptoms (as defined in Appendix III of protocol)~ * Elevated high sensitivity Troponin T or I (above the normal range for individual hospitals)~* GRACE-2.0 score (www.gracescore.org) of either:~  * ≥118 (corresponding to 6-month death \>6%) OR~ * ≥90 but \<118 (corresponding to 6-month death \>3% but \<6%)~* If GRACE 2.0 score ≥90 or \<118 must have at least one additional high risk feature:~  * Anterior location of ECG changes (leads V2 - V5)~ * ST-segment depression in 2 contiguous leads (any territory) of 0.15mV/ 1.5mm.~ * Diabetes Mellitus on medication~ * High-sensitivity Troponin I or T 3 x ULN~* Onset of ischaemic symptoms at any time prior to admission but most recent episode within 12 hours to admission~* Intention to perform angiography and, if indicated, follow-on revascularisation~* Provision of assent or written consent~* Randomisation must be performed within 6 hours of admission~Exclusion Criteria~* ST elevation myocardial infarction~* Evident type 2 myocardial infarction (e.g. anaemia)~* Evidence of previous known cardiomyopathy~* Cardiogenic Shock~* Known severe valvular heart disease~* Need for urgent PCI according to ESC Guidelines (haemodynamic instability, VT, VF, recurrent or persistent pain)~* Any contraindication to PCI~* Current participation in another intervention trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A: Immediate angiography (Type: OTHER): Immediate angiography with follow-on revascularisation if indicated
- Group B: Standard of care angiography (Type: OTHER): Standard of care angiography with follow-on revascularisation if indicated (within 3-4 days, but will vary depending on recruiting centre)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with bullous pemphigoid~* Stable dose of prednisone at or above 10mg per day but no greater than 1 mg/kg/day~* Weigh between 40-120kg~* total IgE level up to 5000 IU/mL~Exclusion Criteria:~* Use of rituximab within 1 year~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- QGE031 (Type: EXPERIMENTAL): QGE031 240 mg Q2W s.c.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to Match Q2W s.c.
- Open Label QGE031 (Type: EXPERIMENTAL): Open Label QGE031 Q2W s.c.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Web-based Platform to Conduct Trials of mHealth Apps for Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* age over 18~* diagnosis of hypertension~* interested in using an app for hypertension management~* access to a smartphone with internet connection~* access to a blood pressure monitoring device (in home or community setting, e.g., pharmacy)~Exclusion Criteria:~* participant-reported BP within target within the 2 weeks prior to enrolment. Target range for patients with diabetes is systolic BP \<130 mm Hg and diastolic BP \< 80 mm Hg; for those without diabetes, target range is systolic BP \<140 mm Hg and diastolic BP \< 90 mm Hg according to Hypertension Canada guidelines~* emergent hypertensive concerns with systolic BP ≥180 mmHg or diastolic BP ≥120 within the 2 weeks prior to enrolment~* current use of a mobile app for hypertension management~* pregnancy~* not living in Canada~* unwillingness or inability to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention App Group (Type: EXPERIMENTAL): The intervention group will be instructed to download the chosen hypertension mobile health app (Sphygmo BP) via a link provided on the platform. The hypertension app has blood pressure tracking and monitoring features and they are instructed to use the app. They will also receive a link to the Heart and Stroke foundation website which includes information on hypertension management and measuring blood pressure.
- Educational Control Group (Type: NO_INTERVENTION): The control will comprise usual care including any anti-hypertensive medication and lifestyle changes, and the link to the Heart and Stroke Foundation website which includes information on hypertension management and measuring blood pressure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Imaging Study of Glioblastomas Treated With Avastin

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histological diagnosis of glioblastoma with clinical or radiological evidence of progression as indicated by the RANO criteria 19~* Previous radiation and temozolomide chemotherapy~* Patients must be receiving Avastin chemotherapy as second-line treatment if in the Avastin group~* Study-specific consent~Exclusion Criteria:~* Failure to meet inclusion criteria~* Pregnant or lactating patients~* Allergy to iodine or CT contrast precludes DECT component of study~* Claustrophobia precludes MR Spectroscopy component of study~* Internal metal which would preclude an MRI scan

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- DECT/MR Spectroscopy +Avastin (Type: ACTIVE_COMPARATOR): -15 Glioma Patients with progression will undergo DECT and MRS before Avastin (10 mg/kg iv q2 weeks until progression) and 3 months later
- DECT/MR Spectroscopy no Avastin (Type: ACTIVE_COMPARATOR): 15 glioma patients not receiving Avastin for recurrence studied in the same manner as Arm 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ventavis® Registry Protocol

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Have a current diagnosis of WHO Group I PAH~2. Have initiated therapy with commercial Ventavis® administered via portable nebulizer at least 3 months prior to study enrollment, either with commercial product or from participation in Actelion's Clinical Study AC-063A302~3. Age \> or = 18 years old at the time of enrollment~Exclusion Criteria:~1. Meet the criteria for inclusion into WHO Groups II, III, IV or V PAH~2. Are not currently on commercial Ventavis®~3. Have initiated therapy with commercial Ventavis® administered via portable nebulizer less than 3 months prior to study enrollment

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): Patients with WHO Group I pulmonary arterial hypertension (PAH) who have been receiving therapy with Ventavis® for at least 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Volume Imaging Using Diagnostic Ultrasound

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older~* Must be scheduled to have a musculoskeletal (bone, ligament, muscle, tendon) ultrasound performed as part of their routine clinical care.~Exclusion Criteria:~* Unable to lie flat on ultrasound table.~* Subjects under 18 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Volume Imaging scan (Type: EXPERIMENTAL): New type of ultrasound scan using General Electric US scanner, Model is a GE Logiq E9.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with moderate to severe plaque psoriasis at least 6 months prior to Visit 1~* Plaque-type psoriasis covering ≥10% of body surface area (BSA) at Visit 1 and Visit 2;~* Psoriasis Area and Severity Index (PASI) score ≥12 at Visit 1 and Visit 2;~* Static Physician's Global Assessment (sPGA) score ≥3 at Visit 1 and Visit 2;~* Body Mass Index (BMI) ≤40 at Visit 1.~Exclusion Criteria:~* Medical history of treatment failure to any systemic agents for plaque psoriasis;~* Presence of erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis or other skin conditions at (e.g., clinically-significant eczema or severe acne) that could interfere with study evaluations at Visit 1;~* Presence or history of any itch due to underlying conditions other than plaque psoriasis which cause or influence pruritus of the skin (e.g., drug induced pruritus, significant other systemic diseases with itch) within 12 months prior to Visit 1;~* History of a clinically-significant infection (e.g., that required oral antimicrobial therapy) within 8 weeks prior to Visit 2;~* History of infections requiring hospitalization or parenteral antibiotic, antiviral, antifungal or antiparasitic therapy within 6 months prior to Visit 2 and no history of recurrent infections or conditions predisposing to chronic infections (e.g., bronchiectasis, chronic osteomyelitis);

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- JTE-051 Dose 1 (Type: EXPERIMENTAL): One dose of study drug by mouth daily for 12 weeks
- JTE-051 Dose 2 (Type: EXPERIMENTAL): One dose of study drug by mouth daily for 12 weeks
- JTE-051 Dose 3 (Type: EXPERIMENTAL): One dose of study drug by mouth daily for 12 weeks
- JTE-051 Dose 4 (Type: EXPERIMENTAL): One dose of study drug by mouth daily for 12 weeks
- Placebo (Type: EXPERIMENTAL): One dose of study drug by mouth daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Definite MS as defined by revised McDonald criteria.~* Bilateral distal symmetric burning pain involving both feet for at least three months.~* Baseline weekly average pain rating equal to four or greater on 0-10 numerical scale.~* Stable MS medication and pain-related medications for 8 weeks prior to screening.~* Must come to Research Center for appointments~Exclusion Criteria:~* Topical treatment with lidocaine, capsaicin, or other topical analgesics within 3 months prior to screening.~* Any treatment with opioid analgesics or tramadol within 3 months prior to screening.~* Hypersensitivity to Lidoderm, lidocaine, or other local anesthetics.~* Hypersensitivity or inability to tolerate opioid analgesics.~* Current treatment with a total of 3 or more antidepressant or anticonvulsant drugs for pain.~* Current treatment with Class I anti-arrhythmic agents at baseline.~* Beck Depression Inventory score \> 16 or clinically significant depression or dementia.~* History of suicide attempt or current intent or plan.~* History of excessive alcohol use or any illicit drug use within the past 2 years.~* Lack of adequate birth control in pre-menopausal women of childbearing age.~* Other pain more severe than lower extremity burning pain.~* Open skin lesions in the area where the lidocaine patch is to be applied.~* Cancer within the previous 5 years other than skin cancer.~* MS exacerbation or any treatment with corticosteroids within 3 months prior to screening.~* History of peripheral neuropathy, lower limb amputation, or another neuromuscular syndrome or systemic disorder known to be associated with sensory neuropathy.~* Does not meet criteria of baseline lab values at screening visit.~* Nerve conduction studies consistent with peripheral neuropathy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lidocaine 5% + placebo patch, ER and placebo pills (Type: ACTIVE_COMPARATOR): 5% lidocaine patch used as intervention placebo patch used with extended release oxycodone or with placebo pills and placebo patches a randomized subjects given extended release oxycodone and placebo patches during this treatment placebo pills used with lidocaine 5% patch group and with placebo patch/placebo pill group period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Discontinuation of TNF-alpha Inhibitors in Patients With Spondyloarthritis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. At least 12 months of treatment with infliximab, etanercept and adalimumab.~2. Diagnosis of spondylarthritis according to the European Spondyloarthritis Study Group (ESSG) criteria or modified New York Criteria~3. No clinical active disease, defined as a BASDAI score \< 4.~4. Among other issues: Age \>18 years; written informed consent, adequate birth control; no contraindications for anti-TNF-alpha-therapy~Exclusion Criteria:~1. Treatment with disease modifying anti-rheumatic drugs within 4 weeks before screening~2. Oral, intraarticular, intramuscular or intravenous glucocorticoid within 4 weeks before screening~3. Pregnancy or lactation~4. HIV, hepatitis B or C, tuberculosis, other infections~5. Malignancies~6. Other serious concomitant diseases (uncontrolled/severe kidney, liver, haematological, gastrointestinal, endocrine, cardiovascular, pulmonary, neurological ore cerebral disease (including demyelinating disease)~7. Contraindications to anti-TNF-alpha-therapy~8. Contraindications to MRI

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 2 (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Image-guided Adaptive Radiotherapy for Cervix Cancer: Patient Image Acquisition

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histological diagnosis of cervix cancer~* Prescription of radiation treatment to the primary cancer~Exclusion Criteria:~* Prior radiation treatment to the pelvis

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cervix cancer patients (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients eligible for autologous stem cell transplant for multiple myeloma; planned use of filgrastim (GCSF) for stem cell mobilization~* Ability to give informed consent~* Glomerular filtration rate (GFR) \> 30 ml/minute~* Liver function tests \< 2.5 x upper limit of normal (ULN)~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2 or less~* Based on prior therapy patients will be classified into two categories:~  * Initial mobilizers with no exposure to alkylators~ * Remobilizers or with prior exposure to alkylators or with greater than 5 cycles of lenalidomide therapy prior to mobilization~Exclusion Criteria:~* Use of a monoamine oxidase inhibitor (MAO-I) during or within 2 weeks of desipramine therapy~* Concomitant therapy with any drugs shown to have major interactions with desipramine~* Concurrent use of drugs that are contraindicated with desipramine~* Myocardial infarction in preceding 4 weeks; history of uncontrolled cardiac arrhythmias or family history of sudden cardiac death; baseline corrected QT (QTc) \> 460 msec~* Active alcohol abuse~* Bipolar disorder~* Untreated active major depression~* History of seizures in the past 3 years~* Pregnancy and lactation; refusal to use adequate contraception~* Uncontrolled thyroid disease~* GCSF or pegfilgrastim use within 14 days prior to enrollment~* Bortezomib, Revlimid or thalidomide use within 7 days of enrollment~* Patients with sickle cell disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (desipramine, filgrastim) (Type: EXPERIMENTAL): Participants received desipramine hydrochloride PO daily on days -3 to +4 and filgrastim PO BID on days 1-4. Stem cell collection began on day 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older~* Any patient undergoing elective hand surgery~Exclusion Criteria:~* Any patient with a traumatic open wound (only surgically created wounds will be included)~* History of chronic pain~* History of narcotic addiction~* History of recreational drug dependency~* History of psychiatric pathology~* Allergy to local anesthetics, recombinant human thrombin or tranexamic acid~* Any patient receiving a supra/infraclavicular block for anesthesia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: t

Study Arms:
- Topical lidocaine and bupivacaine alone (Type: EXPERIMENTAL): In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine
- Topical lidocaine and bupivacaine with thrombin (Type: EXPERIMENTAL): In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine, 10000 units of thrombin
- Topical lidocaine and bupivacaine with thrombin and tranexamic acid (Type: EXPERIMENTAL): In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine, 10000 units of thrombin, and 500 mg of tranexamic acid
- Topical lidocaine and bupivacaine with thrombin and aminocaproic acid (Type: EXPERIMENTAL): In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine, 10000 units of thrombin, and 1000 mg of aminocaproic acid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues